KNSA
Kiniksa InternationalCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive pivotal/late-stage toplines or a strategic partnership that materially de-risks programs and extends cash runway would prompt rapid multiple expansion and re-rating toward the bull target.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -12.5.
What can break
Clinical trial failure or safety signal
Momentum
77
Value
60
Sentiment
26
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $36.49 · Bull $54.74 · Bear $18.25
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $55.86
Why
Momentum77 · Δ7d -12.5
Value60 · Δ7d +0.4
Sentiment26 · Δ7d +9.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
77
34% active weight
Current posture
7d trendSoftening
Δ7d
-12.5
Δ21d
-8.1
Value
60
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.8
Sentiment
26
33% active weight
Current posture
7d trendImproving
Δ7d
+9.5
Δ21d
+19.0
Why this grade
Composite grade C. Momentum 77.0 / Value 59.7 / Sentiment 26.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.73B
Beta
0.06
Shares Out
75.8M
P/E (TTM)
91.6
P/S (TTM)
5.20
P/FCF (TTM)
30.59
Rev YoY
+61.2%
EPS YoY
+230.2%
Gross Margin
+87.5%
Op Margin
+6.4%
Net Debt
-$243.63M
Current Ratio
3.85
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology